{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:25:21Z","timestamp":1791329121963,"version":"4.3.1"},"reference-count":261,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Type 2 diabetes (T2D) and metabolic (dysfunction)-associated steatotic liver disease (MASLD) affect a growing number of individuals worldwide. T2D and MASLD often coexist and substantially elevate the risk of adverse hepatic and cardiovascular clinical outcomes. Several common pathogenetic mechanisms are responsible for T2D and MASLD onset and progression, including insulin resistance, oxidative stress, and low-grade inflammation, among others. The latter can also be induced by gut microbiota and its derived metabolites. Natural bioactive compounds (NBCs) have been reported for their therapeutic potential in both T2D and MASLD. A large amount of evidence obtained from clinical trials suggests that compounds like berberine, curcumin, soluble fibers, and omega-3 fatty acids exhibit significant hypoglycemic, hypolipidemic, and hepatoprotective activity in humans and may be employed as adjunct therapy in T2D and MASLD management. In this review, the role of the most studied NBCs in the management of T2D and MASLD is discussed, emphasizing recent clinical evidence supporting these compounds\u2019 efficacy and safety. Also, prebiotics that act against metabolic dysfunction by modulating gut microbiota are evaluated.<\/jats:p>","DOI":"10.3390\/ph18020279","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:49:27Z","timestamp":1739965767000},"page":"279","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3717-1386","authenticated-orcid":false,"given":"Daniela","family":"Ciob\u00e2rc\u0103","sequence":"first","affiliation":[{"name":"Department 2, Faculty of Nursing and Health Sciences, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 23 Gheorghe Marinescu Street, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Florinela","family":"C\u0103toi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 2-4 Victor Babes Street, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gavrila\u0219","sequence":"additional","affiliation":[{"name":"Department 2, Faculty of Nursing and Health Sciences, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 23 Gheorghe Marinescu Street, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-5723","authenticated-orcid":false,"given":"Roxana","family":"Banc","sequence":"additional","affiliation":[{"name":"Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 6 Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-5060","authenticated-orcid":false,"given":"Doina","family":"Miere","sequence":"additional","affiliation":[{"name":"Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 6 Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-3546","authenticated-orcid":false,"given":"Lorena","family":"Filip","sequence":"additional","affiliation":[{"name":"Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 6 Louis Pasteur Street, 400349 Cluj-Napoca, Romania"},{"name":"Academy of Romanian Scientists (AOSR), 3 Ilfov Street, 050044 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., and Xu, Q. (2023). Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. Front. Endocrinol., 21.","DOI":"10.3389\/fendo.2023.1161521"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"23","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical Update: Cardiovascular Disease in Diabetes Mellitus","volume":"133","author":"Hess","year":"2016","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Samy, A.M., Kandeil, M.A., Sabry, D., Abdel-Ghany, A.A., and Mahmoud, M.O. (2024). From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e30387"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus\u2014Mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","first-page":"E168","article-title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association","volume":"42","author":"Welty","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Haldrup","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Crudele, L., Gadaleta, R.M., Cariello, M., and Moschetta, A. (2023). Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. eBioMedicine, 97.","DOI":"10.1016\/j.ebiom.2023.104821"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., and Miele, L. (2021). Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut\u2013Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126485"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc23-1937","article-title":"Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes","volume":"47","author":"Shang","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Shahzad, N., Alzahrani, A.R., Aziz Ibrahim, I.A., Shahid, I., Alanazi, I.M., Falemban, A.H., Imam, M.T., Mohsin, N., Azlina, M.F.N., and Arulselvan, P. (2024). Therapeutic strategy of biological macromolecules based natural bioactive compounds of diabetes mellitus and future perspectives: A systematic review. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e24207"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cjca.2017.12.007","article-title":"The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes","volume":"34","author":"Stahel","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","article-title":"Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: Results of the Dyslipidaemia International Study","volume":"28","author":"Leiter","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Katzmann, J.L., St\u00fcrzebecher, P.E., Kruppert, S., and Laufs, U. (2024). LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: A simulation study. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50847-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.nut.2007.11.008","article-title":"Lifestyle intervention in the management of metabolic syndrome: Could we improve adherence issues?","volume":"24","author":"Fappa","year":"2008","journal-title":"Nutrition"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrd2005","article-title":"Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy","volume":"5","author":"Grundy","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: Data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: From obesity to metabolic syndrome and diabetes","volume":"12","author":"Valerio","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bellavite, P., Fazio, S., and Affuso, F. (2023). A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance\/Hyperinsulinemia and Cardiovascular Prevention. Molecules, 28.","DOI":"10.3390\/molecules28114491"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1194\/jlr.R087510","article-title":"Muscle and adipose tissue insulin resistance: Malady without mechanism?","volume":"60","author":"Fazakerley","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of Insulin Action and Insulin Resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: Principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/cphy.c190029","article-title":"Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake","volume":"10","author":"Merz","year":"2020","journal-title":"Compr. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"da Silva Rosa, S.C., Nayak, N., Caymo, A.M., and Gordon, J.W. (2020). Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiol. Rep., 8.","DOI":"10.14814\/phy2.14607"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00125-024-06104-9","article-title":"The insulin resistant brain: Impact on whole-body metabolism and body fat distribution","volume":"67","author":"Heni","year":"2024","journal-title":"Diabetologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: From bench to patient care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.gastrohep.2022.02.005","article-title":"Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)","volume":"45","author":"Albillos","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.3390\/cimb44120410","article-title":"Reduced Tyrosine and Serine-632 Phosphorylation of Insulin Receptor Substrate-1 in the Gastrocnemius Muscle of Obese Zucker Rat","volume":"44","author":"Ola","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: Insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cyto.2011.10.001","article-title":"Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF-\u03baB pathway in 3T3-L1 adipocytes","volume":"57","author":"Lira","year":"2012","journal-title":"Cytokine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-3-319-48382-5_18","article-title":"Adiponectin-Resistance in Obesity","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"ref_45","first-page":"1864","article-title":"Serine Phosphorylation of Insulin Receptor Substrate-1: A Novel Target for the Reversal of Insulin Resistance","volume":"15","author":"Sykiotis","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications","volume":"94","author":"Goldberg","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yaribeygi, H., Sathyapalan, T., Atkin, S.L., and Sahebkar, A. (2020). Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid. Med. Cell. Longev., 9.","DOI":"10.1155\/2020\/8609213"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41387-024-00300-7","article-title":"Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease","volume":"14","author":"Wang","year":"2024","journal-title":"Nutr. Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/endo.143.2.8623","article-title":"Minireview: Secondary \u03b2-Cell Failure in Type 2 Diabetes\u2014A Convergence of Glucotoxicity and Lipotoxicity","volume":"143","author":"Poitout","year":"2002","journal-title":"Endocrinology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/db12-1115","article-title":"Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?","volume":"62","author":"Dixit","year":"2013","journal-title":"Diabetes"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Menini, S., Iacobini, C., Vitale, M., and Pugliese, G. (2020). The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders. Cells, 9.","DOI":"10.3390\/cells9081812"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Anand, S., and Mande, S.S. (2022). Host-microbiome interactions: Gut-Liver axis and its connection with other organs. NPJ Biofilms Microbiomes, 8.","DOI":"10.1038\/s41522-022-00352-6"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nawrot, M., Peschard, S., Lestavel, S., and Staels, B. (2021). Intestine-liver crosstalk in type 2 diabetes and non-alcoholic fatty liver disease. Metabolism, 123.","DOI":"10.1016\/j.metabol.2021.154844"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Mateos, R., and Albillos, A. (2021). The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.660179"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3920\/BM2016.0230","article-title":"Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes","volume":"8","author":"Gonai","year":"2017","journal-title":"Benef. Microbes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Abouelkheir, M., Taher, I., Eladl, A.S.R., Shabaan, D.A., Soliman, M.F.M., and Taha, A.E. (2023). Detection and Quantification of Some Ethanol-Producing Bacterial Strains in the Gut of Mouse Model of Non-Alcoholic Fatty Liver Disease: Role of Metformin. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050658"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sharma, B.R., Jaiswal, S., and Ravindra, P.V. (2022). Modulation of gut microbiota by bioactive compounds for prevention and management of type 2 diabetes. Biomed. Pharmacother., 152.","DOI":"10.1016\/j.biopha.2022.113148"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dixit, V., Joseph Kamal, S.W., Bajrang Chole, P., Dayal, D., Chaubey, K.K., Pal, A.K., Xavier, J., Manjunath, B.T., and Bachheti, R.K. (2023). Functional Foods: Exploring the Health Benefits of Bioactive Compounds from Plant and Animal Sources. J. Food Qual., 2023.","DOI":"10.1155\/2023\/5546753"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Noce, A., Di Lauro, M., Di Daniele, F., Pietroboni Zaitseva, A., Marrone, G., Borboni, P., and Di Daniele, N. (2021). Natural Bioactive Compounds Useful in Clinical Management of Metabolic Syndrome. Nutrients, 13.","DOI":"10.3390\/nu13020630"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Figueiredo, P.S., Inada, A.C., Fernandes, M.R., Arakaki, D.G., De C\u00e1ssia Freitas, K., De C\u00e1ssia Avellaneda Guimar\u00e3es, R., do Nascimento, V.A., and Hiane, P.A. (2018). An overview of novel dietary supplements and food ingredients in patients with metabolic syndrome and non-alcoholic fatty liver disease. Molecules, 23.","DOI":"10.3390\/molecules23040877"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y., and Liu, W.J. (2021). The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid. Med. Cell. Longev., 2021.","DOI":"10.1155\/2021\/2074610"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Shrivastava, S., Sharma, A., Saxena, N., Bhamra, R., and Kumar, S. (2023). Addressing the preventive and therapeutic perspective of berberine against diabetes. Heliyon, 9.","DOI":"10.1016\/j.heliyon.2023.e21233"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, Y., Zhang, Y., Xu, N., and Hou, C. (2022). Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2022.1015045"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.metabol.2008.01.013","article-title":"Efficacy of berberine in patients with type 2 diabetes mellitus","volume":"57","author":"Yin","year":"2008","journal-title":"Metabolism"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.metabol.2009.07.029","article-title":"Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression","volume":"59","author":"Zhang","year":"2010","journal-title":"Metabolism"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.talanta.2010.01.015","article-title":"Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics","volume":"81","author":"Gu","year":"2010","journal-title":"Talanta"},{"key":"ref_71","first-page":"167","article-title":"Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes","volume":"19","author":"Putignano","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"ref_72","first-page":"89","article-title":"Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins","volume":"8","author":"Bellone","year":"2015","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/etm.2015.2585","article-title":"Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography","volume":"10","author":"Dai","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yan, H.M., Xia, M.F., Wang, Y., Chang, X.X., Yao, X.Z., Rao, S.X., Zeng, M.S., Tu, Y.F., Feng, R., and Jia, W.P. (2015). Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134172"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12967-016-0982-x","article-title":"Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease","volume":"14","author":"Chang","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_77","first-page":"291","article-title":"Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial","volume":"75","author":"Koperska","year":"2024","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.metabol.2008.01.037","article-title":"Combination of simvastatin with berberine improves the lipid-lowering efficacy","volume":"57","author":"Kong","year":"2008","journal-title":"Metabolism"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Schmidt, A.F., Carter, J.P.L., Pearce, L.S., Wilkins, J.T., Overington, J.P., Hingorani, A.D., and Casas, J.P. (2020). PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev., 2020.","DOI":"10.1002\/14651858.CD011748.pub3"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/aps.2016.134","article-title":"Lowering serum lipids via PCSK9-targeting drugs: Current advances and future perspectives","volume":"38","author":"He","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-024-05011-2","article-title":"The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: A meta-analysis and systematic review","volume":"22","author":"Nie","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Pivari, F., Mingione, A., Brasacchio, C., and Soldati, L. (2019). Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment. Nutrients, 11.","DOI":"10.3390\/nu11081837"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctim.2017.05.006","article-title":"Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial","volume":"33","author":"Panahi","year":"2017","journal-title":"Complement. Ther. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41387-024-00274-6","article-title":"The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: A double-blinded randomized clinical trial","volume":"14","author":"Asghari","year":"2024","journal-title":"Nutr. Diabetes"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/mnfr.201200131","article-title":"Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: A double-blind, placebo-controlled trial","volume":"57","author":"Na","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_86","first-page":"567","article-title":"The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial","volume":"6","author":"Rahimi","year":"2016","journal-title":"Avicenna J. Phytomed."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12937-024-01022-3","article-title":"Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: A randomized controlled trial","volume":"23","author":"Yaikwawong","year":"2024","journal-title":"Nutr. J."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yaikwawong, M., Jansarikit, L., Jirawatnotai, S., and Chuengsamarn, S. (2024). The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial. Nutrients, 16.","DOI":"10.3390\/nu16152441"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ptr.5659","article-title":"Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial","volume":"30","author":"Rahmani","year":"2016","journal-title":"Phytother. Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Saadati, S., Sadeghi, A., Mansour, A., Yari, Z., Poustchi, H., Hedayati, M., Hatami, B., and Hekmatdoost, A. (2019). Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-1055-4"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Naseri, K., Saadati, S., Yari, Z., Askari, B., Mafi, D., Hoseinian, P., Asbaghi, O., Hekmatdoost, A., and de Courten, B. (2022). Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 14.","DOI":"10.3390\/nu14153224"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/ptr.7764","article-title":"Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial","volume":"37","author":"Sharifi","year":"2023","journal-title":"Phytother. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Pathomwichaiwat, T., Jinatongthai, P., Prommasut, N., Ampornwong, K., Rattanavipanon, W., Nathisuwan, S., and Thakkinstian, A. (2023). Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0288997"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ptr.8051","article-title":"Effects of curcumin\/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index, and anthropometric indices in non-alcoholic fatty liver patients: An umbrella meta-analysis","volume":"38","author":"Dehghani","year":"2024","journal-title":"Phytother. Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Servida, S., Panzeri, E., Tomaino, L., Marfia, G., Garzia, E., Appiani, G.C., Moroncini, G., De Gennaro Colonna, V., La Vecchia, C., and Vigna, L. (2023). Overview of Curcumin and Piperine Effects on Glucose Metabolism: The Case of an Insulinoma Patient\u2019s Loss of Consciousness. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076621"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gu, W., Geng, J., Zhao, H., Li, X., and Song, G. (2022). Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Int. J. Clin. Pract., 2022.","DOI":"10.1155\/2022\/9734738"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nutres.2012.06.003","article-title":"Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus","volume":"32","author":"Bhatt","year":"2012","journal-title":"Nutr. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3945\/ajcn.115.117440","article-title":"Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial","volume":"103","author":"Thazhath","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc16-0499","article-title":"Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial","volume":"39","author":"Timmers","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","article-title":"Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial","volume":"111","author":"Bo","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1039\/C9FO01075K","article-title":"The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease","volume":"10","author":"Hoseini","year":"2019","journal-title":"Food Funct."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Mahjabeen, W., Khan, D.A., and Mirza, S.A. (2022). Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement. Ther. Med., 66.","DOI":"10.1016\/j.ctim.2022.102819"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study","volume":"114","author":"Faghihzadeh","year":"2015","journal-title":"Br. J. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"47","author":"Chen","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Kreuzfeldt","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Rafiee, S., Mohammadi, H., Ghavami, A., Sadeghi, E., Safari, Z., and Askari, G. (2021). Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Complement. Ther. Clin. Pract., 42.","DOI":"10.1016\/j.ctcp.2020.101281"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/ajcn\/nqab250","article-title":"The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials","volume":"114","author":"Jayedi","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Shaito, A., Posadino, A.M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W.M., Eid, A.H., and Nasrallah, G.N. (2020). Potential Adverse Effects of Resveratrol: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062084"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Khoo, H.E., Azlan, A., Tang, S.T., and Lim, S.M. (2017). Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Res., 61.","DOI":"10.1080\/16546628.2017.1361779"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Mao, T., Akshit, F.N.U., and Mohan, M.S. (2023). Effects of anthocyanin supplementation in diet on glycemic and related cardiovascular biomarkers in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1199815"},{"key":"ref_112","first-page":"17","article-title":"Anti-hyperglycemic effect of Vaccinium arctostaphylos in type 2 diabetic patients: A randomized controlled trial","volume":"20","author":"Kianbakht","year":"2013","journal-title":"Forsch. Komplementmed."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3945\/jn.114.205674","article-title":"Purified Anthocyanin Supplementation Reduces Dyslipidemia, Enhances Antioxidant Capacity, and Prevents Insulin Resistance in Diabetic Patients","volume":"145","author":"Li","year":"2015","journal-title":"J. Nutr."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12986-020-00498-0","article-title":"Anthocyanins increase serum adiponectin in newly diagnosed diabetes but not in prediabetes: A randomized controlled trial","volume":"17","author":"Yang","year":"2020","journal-title":"Nutr. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Stote, K.S., Wilson, M.M., Hallenbeck, D., Thomas, K., Rourke, J.M., Sweeney, M.I., Gottschall-Pass, K.T., and Gosmanov, A.R. (2020). Effect of Blueberry Consumption on Cardiometabolic Health Parameters in Men with Type 2 Diabetes: An 8-Week, Double-Blind, Randomized, Placebo-Controlled Trial. Curr. Dev. Nutr., 4.","DOI":"10.1093\/cdn\/nzaa030"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/ptr.7038","article-title":"Impact of short-term bilberry supplementation on glycemic control, cardiovascular disease risk factors, and antioxidant status in Chinese patients with type 2 diabetes","volume":"35","author":"Chan","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00011-021-01438-1","article-title":"Potential of anthocyanin as an anti-inflammatory agent: A human clinical trial on type 2 diabetic, diabetic at-risk and healthy adults","volume":"70","author":"Nikbakht","year":"2021","journal-title":"Inflamm. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1039\/c3fo60495k","article-title":"Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans","volume":"5","author":"Chang","year":"2014","journal-title":"Food Funct."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zhang, P.W., Chen, F.X., Li, D., Ling, W.H., and Guo, H.H. (2015). A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients with Nonalcoholic Fatty Liver Disease. Medicine, 94.","DOI":"10.1097\/MD.0000000000000758"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1002\/ptr.7199","article-title":"The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: A double-blind randomized clinical trial","volume":"35","author":"Sangsefidi","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Bayram, H.M., Iliaz, R., and Gunes, F.E. (2024). Effects of Cornus mas L. on anthropometric and biochemical parameters among metabolic associated fatty liver disease patients: Randomized clinical trial. J. Ethnopharmacol., 318.","DOI":"10.1016\/j.jep.2023.117068"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Khan, N.N., Zurayyir, E.J., Almuslem, M.Y., Alshamrani, R., Alamri, R.A., Sulaimani, G.H.T., Sulimani, M.H.T., Albalawi, M.S.F., Alqahani, R.M.A., and Alanazi, E.M. (2024). Anthocyanins as Adjuvant Treatment for Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Cureus, 16.","DOI":"10.7759\/cureus.63445"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Frumuzachi, O., Kieserling, H., Rohn, S., Mocan, A., and Cri\u0219an, G. (2024). The Impact of Cornelian Cherry (Cornus mas L.) on Cardiometabolic Risk Factors: A Meta-Analysis of Randomised Controlled Trials. Nutrients, 16.","DOI":"10.3390\/nu16132173"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, A.C., Nunes, A.R., Falc\u00e3o, A., Alves, G., and Silva, L.R. (2021). Dietary Effects of Anthocyanins in Human Health: A Comprehensive Review. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070690"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Liu, C.Y., Huang, C.J., Huang, L.H., Chen, I.J., Chiu, J.P., and Hsu, C.H. (2014). Effects of Green Tea Extract on Insulin Resistance and Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes and Lipid Abnormalities: A Randomized, Double-Blinded, and Placebo-Controlled Trial. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091163"},{"key":"ref_126","first-page":"424","article-title":"The Effect of Green Tea versus Sour Tea on Insulin Resistance, Lipids Profiles and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial","volume":"39","author":"Ahadi","year":"2014","journal-title":"Iran. J. Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/oby.2008.505","article-title":"A Catechin-rich Beverage Improves Obesity and Blood Glucose Control in Patients with Type 2 Diabetes","volume":"17","author":"Nagao","year":"2009","journal-title":"Obesity"},{"key":"ref_128","first-page":"157","article-title":"Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial","volume":"16","author":"Hsu","year":"2011","journal-title":"Altern. Med. Rev."},{"key":"ref_129","first-page":"1080","article-title":"The effects of green tea consumption on metabolic and anthropometric indices in patients with Type 2 diabetes","volume":"18","author":"Mousavi","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1515\/jcim-2020-0090","article-title":"Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: A clinical trial","volume":"18","author":"Bazyar","year":"2020","journal-title":"J. Complement. Integr. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Yazdanpanah, Z., Salehi-Abargouei, A., Mozaffari, Z., and Hemayati, R. (2023). The effect of green tea (Camellia sinensis) on lipid profiles and renal function in people with type 2 diabetes and nephropathy: A randomized controlled clinical trial. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1253275"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.dsx.2020.11.004","article-title":"Effect of green tea on glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"15","author":"Asbaghi","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3892\/ijmm.2013.1503","article-title":"Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study","volume":"32","author":"Sakata","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_134","first-page":"28","article-title":"The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease","volume":"1","author":"Pezeshki","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Tabatabaee, S.M., Alavian, S.M., Ghalichi, L., Miryounesi, S.M., Mousavizadeh, K., Jazayeri, S., and Vafa, M.R. (2017). Green Tea in Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial. Hepat. Mon., 17.","DOI":"10.5812\/hepatmon.14993"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"931","DOI":"10.12669\/pjms.334.12571","article-title":"Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients","volume":"33","author":"Hussain","year":"2017","journal-title":"Pak. J. Med. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/ptr.6637","article-title":"Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Mahmoodi","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ejcn.2016.165","article-title":"Liver-related safety assessment of green tea extracts in humans: A systematic review of randomized controlled trials","volume":"70","author":"Isomura","year":"2016","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipi\u010d, M., Frutos, M.J., Galtier, P., Gott, D., and Gundert-Remy, U. (2018). Scientific opinion on the safety of green tea catechins. EFSA J., 16.","DOI":"10.2903\/j.efsa.2018.5239"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.joim.2018.05.006","article-title":"TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: A randomized, double-blind, placebo-controlled trial","volume":"16","author":"Rezazadeh","year":"2018","journal-title":"J. Integr. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/19390211.2022.2107138","article-title":"The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial","volume":"20","author":"Osama","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Inoue, T., Yoshida, K., Sasaki, E., Aizawa, K., and Kamioka, H. (2022). Effect of Lycopene Intake on the Fasting Blood Glucose Level: A Systematic Review with Meta-Analysis. Nutrients, 15.","DOI":"10.3390\/nu15010122"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ptr.6073","article-title":"Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial","volume":"32","author":"Panahi","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Al-Aubaidy, H.A., Dayan, A., Deseo, M.A., Itsiopoulos, C., Jamil, D., Hadi, N.R., and Thomas, C.J. (2021). Twelve-Week Mediterranean Diet Intervention Increases Citrus Bioflavonoid Levels and Reduces Inflammation in People with Type 2 Diabetes Mellitus. Nutrients, 13.","DOI":"10.3390\/nu13041133"},{"key":"ref_145","first-page":"58","article-title":"Cynara scolymus L. in Treatment of Hypercholesterolemic Type 2 Diabetic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial","volume":"11","author":"Kianbakht","year":"2012","journal-title":"J. Med. Plants"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/diacare.23.6.733","article-title":"Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes","volume":"23","author":"Upritchard","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ptr.6046","article-title":"Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial","volume":"32","author":"Homayouni","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00394-019-02105-2","article-title":"The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial","volume":"59","author":"Yari","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Rangboo, V., Noroozi, M., Zavoshy, R., Rezadoost, S.A., and Mohammadpoorasl, A. (2016). The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis. Int. J. Hepatol., 2016.","DOI":"10.1155\/2016\/4030476"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jtcme.2020.02.004","article-title":"The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease","volume":"10","author":"Musolino","year":"2020","journal-title":"J. Tradit. Complement. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","article-title":"The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: An open-labeled randomized controlled trial","volume":"75","author":"Yari","year":"2021","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bcp.14120","article-title":"Hesperidin supplementation has no effect on blood glucose control: A systematic review and meta-analysis of randomized controlled clinical trials","volume":"86","author":"Mohammadi","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Mirarchi, A., Mare, R., Musolino, V., Nucera, S., Mollace, V., Pujia, A., Montalcini, T., Romeo, S., and Maurotti, S. (2022). Bergamot Polyphenol Extract Reduces Hepatocyte Neutral Fat by Increasing Beta-Oxidation. Nutrients, 14.","DOI":"10.3390\/nu14163434"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Moradi, S., Shokri-Mashhadi, N., Saraf-Bank, S., Mohammadi, H., Zobeiri, M., Clark, C.C.T., and Rouhani, M.H. (2021). The effects of Cynara scolymus L. supplementation on liver enzymes: A systematic review and meta-analysis. Int. J. Clin. Pract., 75.","DOI":"10.1111\/ijcp.14726"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11130-015-0503-8","article-title":"Pharmacological Studies of Artichoke Leaf Extract and Their Health Benefits","volume":"70","author":"Salem","year":"2015","journal-title":"Plant Foods Hum. Nutr."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1002\/fsn3.4502","article-title":"Nutritional Benefits of Lycopene and Beta-Carotene: A Comprehensive Overview","volume":"12","author":"Tufail","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.sajb.2023.08.041","article-title":"Potential role of hesperidin in lifestyle disorders: A scoping review","volume":"161","author":"Tayal","year":"2023","journal-title":"S. Afr. J. Bot."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ctim.2018.08.010","article-title":"The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials","volume":"41","author":"Hadi","year":"2018","journal-title":"Complement. Ther. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ptr.1988","article-title":"The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial","volume":"20","author":"Huseini","year":"2006","journal-title":"Phytother. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.phymed.2014.12.010","article-title":"Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial","volume":"22","author":"Gargari","year":"2015","journal-title":"Phytomedicine"},{"key":"ref_163","first-page":"39","article-title":"Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A triple-blinded randomized controlled clinical trial","volume":"15","author":"Gargari","year":"2018","journal-title":"Phytomedicine"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/13813455.2020.1797104","article-title":"Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes","volume":"129","author":"Ghalandari","year":"2023","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1002\/ptr.8273","article-title":"Effect of silymarin on lipid profile and glycemic control in patients with type 2 diabetes mellitus","volume":"38","author":"Ferdowsi","year":"2024","journal-title":"Phytother. Res."},{"key":"ref_166","first-page":"3118","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease.A randomized clinical pilot study","volume":"19","author":"Aller","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis","volume":"15","author":"Mahadeva","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12944-024-02220-y","article-title":"Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: A randomized, double-blind, placebo-controlled trial","volume":"23","author":"Jin","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3748\/wjg.v23.i27.5004","article-title":"Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis","volume":"23","author":"Pereira","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Voroneanu, L., Nistor, I., Dumea, R., Apetrii, M., and Covic, A. (2016). Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Diabetes Res., 2016.","DOI":"10.1155\/2016\/5147468"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jand.2016.07.015","article-title":"Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review","volume":"116","author":"Costello","year":"2016","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/10408390902773052","article-title":"Cinnamon and health","volume":"50","author":"Gruenwald","year":"2010","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2337\/diacare.26.12.3215","article-title":"Cinnamon Improves Glucose and Lipids of People with Type 2 Diabetes","volume":"26","author":"Khan","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1464-5491.2010.03079.x","article-title":"Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: A randomized, placebo-controlled, double-blind clinical trial","volume":"27","author":"Akilen","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.nutres.2012.05.003","article-title":"Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes","volume":"32","author":"Lu","year":"2012","journal-title":"Nutr. Res."},{"key":"ref_177","first-page":"531","article-title":"Effects of Cinnamon Consumption on Glycemic Status, Lipid Profile and Body Composition in Type 2 Diabetic Patients","volume":"3","author":"Vafa","year":"2012","journal-title":"Int. J. Prev. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clnu.2018.03.003","article-title":"Efficacy of cinnamon in patients with type II diabetes mellitus: A randomized controlled clinical trial","volume":"38","author":"Zare","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12937-019-0518-3","article-title":"Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: A randomized, double blind, and controlled clinical trial","volume":"19","author":"Davari","year":"2020","journal-title":"Nutr. J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nutres.2013.11.005","article-title":"Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients","volume":"34","author":"Askari","year":"2014","journal-title":"Nutr. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnesp.2018.07.011","article-title":"To what extent does cinnamon administration improve the glycemic and lipid profiles?","volume":"27","author":"Santos","year":"2018","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/nutrit\/nuae058","article-title":"Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: A systematic review and meta-analysis","volume":"83","author":"Gomes","year":"2025","journal-title":"Nutr. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Gu, D.T., Tung, T.H., Jiesisibieke, Z.L., Chien, C.W., and Liu, W.Y. (2022). Safety of Cinnamon: An Umbrella Review of Meta-Analyses and Systematic Reviews of Randomized Clinical Trials. Front. Pharmacol., 18.","DOI":"10.3389\/fphar.2021.790901"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Vajdi, M., Noshadi, N., Bonyadian, A., Golpour-Hamedani, S., Alipour, B., Pourteymour Fard Tabrizi, F., Abbasalizad-Farhangi, M., and Askari, G. (2024). Therapeutic effect of fenugreek supplementation on type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e36649"},{"key":"ref_185","first-page":"1057","article-title":"Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: A double-blind placebo-controlled study","volume":"49","author":"Gupta","year":"2001","journal-title":"J. Assoc. Physicians India"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11655-007-9005-3","article-title":"Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus","volume":"14","author":"Lu","year":"2008","journal-title":"Chin. J. Integr. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"0196","DOI":"10.1024\/0300-9831\/a000206","article-title":"Effect of Fenugreek Seeds on Serum Metabolic Factors and Adiponectin Levels in Type 2 Diabetic Patients","volume":"84","author":"Rafraf","year":"2014","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.4314\/ahs.v19i1.34","article-title":"A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes","volume":"19","author":"Najdi","year":"2019","journal-title":"Afr. Health Sci."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Geberemeskel, G.A., Debebe, Y.G., and Nguse, N.A. (2019). Antidiabetic Effect of Fenugreek Seed Powder Solution (Trigonella foenum-graecum L.) on Hyperlipidemia in Diabetic Patients. J. Diabetes Res., 2019.","DOI":"10.1155\/2019\/8507453"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Hadi, A., Arab, A., Hajianfar, H., Talaei, B., Miraghajani, M., Babajafari, S., Marx, W., and Tavakoly, R. (2020). The effect of fenugreek seed supplementation on serum irisin levels, blood pressure, and liver and kidney function in patients with type 2 diabetes mellitus: A parallel randomized clinical trial. Complement. Ther. Med., 49.","DOI":"10.1016\/j.ctim.2020.102315"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"184","DOI":"10.34172\/jcvtr.33231","article-title":"The effect of Fenugreek seed dry extract supplement on glycemic indices, lipid profile, and prooxidant-antioxidant balance in patients with type 2 diabetes: A double-blind randomized clinical trial","volume":"16","author":"Chehregosha","year":"2024","journal-title":"J. Cardiovasc. Thorac. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/ijp.IJP_17_19","article-title":"Comparison of the efficacy of oral fenugreek seeds hydroalcoholic extract versus placebo in nonalcoholic fatty liver disease; a randomized, triple-blind controlled pilot clinical trial","volume":"52","author":"Babaei","year":"2020","journal-title":"Indian. J. Pharmacol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"134","DOI":"10.14196\/mjiri.31.134","article-title":"Polyphenols and their effects on diabetes management: A review","volume":"31","author":"Aryaeian","year":"2017","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3109\/09637486.2013.775223","article-title":"Effects of ginger (Zingiber officinale) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients","volume":"64","author":"Mahluji","year":"2013","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEG.S234698","article-title":"Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"13","author":"Rafie","year":"2020","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctim.2013.12.017","article-title":"The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Talaei","year":"2014","journal-title":"Complement. Ther. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/09637486.2014.880671","article-title":"The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus","volume":"65","author":"Arablou","year":"2014","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1515\/jcim-2014-0021","article-title":"The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes","volume":"12","author":"Shidfar","year":"2015","journal-title":"J. Complement. Integr. Med."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Makhdoomi Arzati, M., Mohammadzadeh Honarvar, N., Saedisomeolia, A., Anvari, S., Effatpanah, M., Makhdoomi Arzati, R., Yekaninejad, M.S., Hashemi, R., and Djalali, M. (2017). The Effects of Ginger on Fasting Blood Sugar, Hemoglobin A1c, and Lipid Profiles in Patients with Type 2 Diabetes. Int. J. Endocrinol. Metab., 15.","DOI":"10.5812\/ijem.57927"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Carvalho, G.C.N., Lira-Neto, J.C.G., Ara\u00fajo, M.F.M., Freitas, R.W.J., Zanetti, M.L., and Damasceno, M.M.C. (2020). Effectiveness of ginger in reducing metabolic levels in people with diabetes: A randomized clinical trial. Rev. Lat. Am. Enferm., 28.","DOI":"10.1590\/1518-8345.3870.3369"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Ebrahimzadeh, A., Ebrahimzadeh, A., Mirghazanfari, S.M., Hazrati, E., Hadi, S., and Milajerdi, A. (2022). The effect of ginger supplementation on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med., 65.","DOI":"10.1016\/j.ctim.2022.102802"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Rahimlou, M., Yari, Z., Hekmatdoost, A., Alavian, S.M., and Keshavarz, S.A. (2016). Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat. Mon., 16.","DOI":"10.5812\/hepatmon.34897"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/19390211.2023.2263788","article-title":"The Effects of Ginger (Zingiber Officinale Roscoe) on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blinded Placebo-Controlled Clinical Trial","volume":"21","author":"Ghoreishi","year":"2024","journal-title":"J. Diet. Suppl."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Huang, F.Y., Deng, T., Meng, L.X., and Ma, X.L. (2019). Dietary ginger as a traditional therapy for blood sugar control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Medicine, 98.","DOI":"10.1097\/MD.0000000000015054"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/dc18-1126","article-title":"Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"42","author":"Jovanovski","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/10408398.2021.1981228","article-title":"The effect of guar gum consumption on the lipid profile in type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Li","year":"2023","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ejcn.2016.156","article-title":"Effect of inulin-type fructans on blood lipid profile and glucose level: A systematic review and meta-analysis of randomized controlled trials","volume":"71","author":"Liu","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Stachowska, E., Portincasa, P., Jamio\u0142-Milc, D., Maciejewska-Markiewicz, D., and Skonieczna-\u017bydecka, K. (2020). The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD\u2014A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 12.","DOI":"10.3390\/nu12113460"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3390\/nu5041417","article-title":"Fiber and Prebiotics: Mechanisms and Health Benefits","volume":"5","author":"Slavin","year":"2013","journal-title":"Nutrients"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/ejcn.2009.60","article-title":"The effects of psyllium on lipoproteins in type II diabetic patients","volume":"63","author":"Sartore","year":"2009","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bcdf.2013.02.003","article-title":"Psyllium improves glycemic control in patients with type-2 diabetes mellitus","volume":"1","author":"Feinglos","year":"2013","journal-title":"Bioact. Carbohydr. Diet. Fibre"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3945\/ajcn.115.106989","article-title":"Psyllium fiber improves glycemic control proportional to loss of glycemic control: A meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus","volume":"102","author":"Gibb","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7762\/cnr.2018.7.1.31","article-title":"The Effect of Soluble Fiber Supplementation on Metabolic Syndrome Profile among Newly Diagnosed Type 2 Diabetes Patients","volume":"7","author":"Abutair","year":"2018","journal-title":"Clin. Nutr. Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/19390211.2017.1358791","article-title":"Short-Term Supplementation of a Moderate Carbohydrate Diet with Psyllium Reduces Fasting Plasma Insulin and Tumor Necrosis Factor-\u03b1 in Patients with Type 2 Diabetes Mellitus","volume":"15","author":"Kamalpour","year":"2018","journal-title":"J. Diet. Suppl."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4093\/dmj.2013.37.2.140","article-title":"Effects of High-Performance Inulin Supplementation on Glycemic Control and Antioxidant Status in Women with Type 2 Diabetes","volume":"37","author":"Dehghan","year":"2013","journal-title":"Diabetes Metab. J."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/09637486.2013.836738","article-title":"Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized-controlled clinical trial","volume":"65","author":"Dehghan","year":"2014","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.nut.2013.09.005","article-title":"Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized controlled clinical trial","volume":"30","author":"Dehghan","year":"2014","journal-title":"Nutrition"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2015.10.009","article-title":"The effect of enriched chicory inulin on liver enzymes, calcium homeostasis and hematological parameters in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial","volume":"10","author":"Farhangi","year":"2016","journal-title":"Prim. Care Diabetes"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1017\/S0007114513001025","article-title":"Improvement of the metabolic syndrome profile by soluble fibre\u2014Guar gum\u2014In patients with type 2 diabetes: A randomized clinical trial","volume":"110","author":"Silva","year":"2013","journal-title":"Br. J. Nutr."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/dom.13604","article-title":"A whey\/guar \u201cpreload\u201d improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial","volume":"21","author":"Watson","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.ejcn.1602127","article-title":"Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study","volume":"59","author":"Daubioul","year":"2005","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_222","first-page":"1771","article-title":"The effect of psyllium on anthropometric measurements and liver enzymes in overweight or obese adults with nonalcoholic fatty liver disease (NAFLD)","volume":"33","author":"Akbarzadeh","year":"2015","journal-title":"Isfahan Med. Sch."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/2008-7802.191865","article-title":"Comparative study on the effect of Plantago psyllium and Ocimum basilicum seeds on anthropometric measures in nonalcoholic fatty liver patients","volume":"7","author":"Akbarian","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Gholami, Z., Clark, C.C.T., and Paknahad, Z. (2024). The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC Endocr. Disord., 24.","DOI":"10.1186\/s12902-024-01608-2"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12967-019-02159-0","article-title":"Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: Results from a GRADE-assessed systematic review and dose\u2013response meta-analysis of 33 randomized controlled trials","volume":"17","author":"Wang","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Javad Alaeian, M., Pourreza, S., Yousefi, M., Golalipour, E., Setayesh, L., Zeinali Khosroshahi, M., Bagheri, R., Ashtary-Larky, D., Wong, A., and Zamani, M. (2023). The effects of guar gum supplementation on glycemic control, body mass and blood pressure in adults: A GRADE-assessed systematic review and meta-analysis of randomized clinical trials. Diabetes Res. Clin. Pract., 199.","DOI":"10.1016\/j.diabres.2023.110604"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Jenko Pra\u017enikar, Z., Mohorko, N., Gmajner, D., Kenig, S., and Petelin, A. (2023). Effects of Four Different Dietary Fibre Supplements on Weight Loss and Lipid and Glucose Serum Profiles during Energy Restriction in Patients with Traits of Metabolic Syndrome: A Comparative, Randomized, Placebo-Controlled Study. Foods, 12.","DOI":"10.3390\/foods12112122"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1080\/10408398.2021.1875977","article-title":"Omega-3 supplementation and diabetes: A systematic review and meta-analysis","volume":"62","author":"Delpino","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0884533612444535","article-title":"\u03a9-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity","volume":"27","author":"Crochemore","year":"2012","journal-title":"Nutr. Clin. Pract."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MCO.0000000000000539","article-title":"Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children","volume":"22","author":"Spooner","year":"2019","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MOL.0b013e328321b3be","article-title":"Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes","volume":"20","author":"Hartweg","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_232","first-page":"615","article-title":"Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients","volume":"53","author":"Saedisomeolia","year":"2012","journal-title":"Singap. Med. J."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/mnfr.201600230","article-title":"Effects of n-3 fatty acid supplements on glycemic traits in Chinese type 2 diabetic patients: A double-blind randomized controlled trial","volume":"60","author":"Zheng","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00394-016-1352-4","article-title":"Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: A randomized, double-blind, placebo-controlled trial","volume":"56","author":"Wang","year":"2017","journal-title":"Eur. J. Nutr."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Jacobo-Cejudo, M.G., Vald\u00e9s-Ramos, R., Guadarrama-L\u00f3pez, A.L., Pardo-Morales, R.V., Mart\u00ednez-Carrillo, B.E., and Harbige, L.S. (2017). Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2 Diabetes Mellitus Patients. Nutrients, 9.","DOI":"10.3390\/nu9060573"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Werida, R.H., Ramzy, A., Ebrahim, Y.N., and Helmy, M.W. (2023). Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: A randomized controlled trial. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01511-2"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.dld.2007.10.003","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Qin, Y., Zhou, Y., Chen, S.H., Zhao, X.L., Ran, L., Zeng, X.L., Wu, Y., Chen, J.L., Kang, C., and Shu, F.R. (2015). Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133496"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients with Nonalcoholic Steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep4.1906","article-title":"Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients with Metabolic Syndrome and NAFLD","volume":"6","author":"Kosek","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-018-0740-x","article-title":"Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: A meta-analysis and meta-regression of randomized controlled trials","volume":"17","author":"Matu","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"He, X.X., Wu, X.L., Chen, R.P., Chen, C., Liu, X.G., Wu, B.J., and Huang, Z.M. (2016). Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162368"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2012.01.028","article-title":"The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease","volume":"57","author":"Li","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D.B., Morgun, A., and Shulzhenko, N. (2020). Role of gut microbiota in type 2 diabetes pathophysiology. eBioMedicine, 51.","DOI":"10.1016\/j.ebiom.2019.11.051"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Hrncir, T., Hrncirova, L., Kverka, M., Hromadka, R., Machova, V., Trckova, E., Kostovcikova, K., Kralickova, P., Krejsek, J., and Tlaskalova-Hogenova, H. (2021). Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms, 9.","DOI":"10.3390\/microorganisms9050957"},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Barchetta, I., Cimini, F.A., Sentinelli, F., Chiappetta, C., Di Cristofano, C., Silecchia, G., Leonetti, F., Baroni, M.G., and Cavallo, M.G. (2023). Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417174"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/ijo.2011.256","article-title":"Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance","volume":"36","author":"Ortega","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3748\/wjg.v23.i4.712","article-title":"Association between endotoxemia and histological features of nonalcoholic fatty liver disease","volume":"23","author":"Kitabatake","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Ojo, O., Wang, X., Ojo, O.O., Brooke, J., Jiang, Y., Dong, Q., and Thompson, T. (2022). The Effect of Prebiotics and Oral Anti-Diabetic Agents on Gut Microbiome in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Nutrients, 14.","DOI":"10.3390\/nu14235139"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/pdi.2285","article-title":"Prebiotics and type 2 diabetes: Targeting the gut microbiota for improved glycaemic control?","volume":"37","author":"Robertson","year":"2020","journal-title":"Pract. Diabetes"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s00394-020-02282-5","article-title":"Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: A randomised controlled trial","volume":"59","author":"Birkeland","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1017\/S0007114516004086","article-title":"Host\u2013microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake","volume":"116","author":"Pedersen","year":"2016","journal-title":"Br. J. Nutr."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.gastro.2017.03.051","article-title":"Supplementation of Diet with Galacto-oligosaccharides Increases Bifidobacteria, but Not Insulin Sensitivity, in Obese Prediabetic Individuals","volume":"153","author":"Canfora","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/dom.14967","article-title":"A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial","volume":"25","author":"Frias","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Reshef, N., Gophna, U., Reshef, L., Konikoff, F., Gabay, G., Zornitzki, T., Knobler, H., and Maor, Y. (2024). Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)\u2014A Randomized Pilot Trial. Nutrients, 16.","DOI":"10.3390\/nu16111571"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/1541-4337.12119","article-title":"Significance of Inulin Fructans in the Human Diet","volume":"14","author":"Schaafsma","year":"2015","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"key":"ref_261","first-page":"305","article-title":"Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics","volume":"104","author":"Macfarlane","year":"2008","journal-title":"J. Appl. Microbiol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/2\/279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:38:16Z","timestamp":1760027896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/2\/279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":261,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ph18020279"],"URL":"https:\/\/doi.org\/10.3390\/ph18020279","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}